Non-small-cell lung cancer: Treatment of late stage disease: Chemotherapeutics and new frontiers

Seminars in Interventional Radiology

Volumn 30, Issue 2, 2013, Pages 191-198

  Scheff, Ronaldj ^a   Schneider, Bryanj ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

chemotherapy; non small cell lung cancer; systemic therapy; targeted therapy

Indexed keywords

EID: 84878398840     PISSN: 07399529     EISSN: 10988963     Source Type: Journal    
DOI: 10.1055/s-0033-1342961     Document Type: Article

References (60)

1. American Cancer Society Cancer facts and figures 2012. Atlanta, GA: 2012. Available at: http://www.cancer.org/acs/groups/content/ @epidemiologysurveilance/documents/document/acspc-031941.pdf
2. Rapp E., Pater J. L., Willan A., et al. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol: 1988; 6 4 633 641
3. Marino P., Pampallona S., Preatoni A., Cantoni A., Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest: 1994; 106 3 861 865 (Pubitemid 24278896)
4. Non-Small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ: 1995; 311 7010 899 909
5. Rami-Porta R., Crowley J. J., Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg: 2009; 15 1 4 9
6. Postmus P. E., Brambilla E., Chansky K., et al. International Association for the Study of Lung Cancer International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. J Thorac Oncol: 2007; 2 8 686 693 (Pubitemid 47357520)
7. Tanvetyanon T., Robinson L. A., Schell M. J., et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol: 2008; 26 7 1142 1147
8. Ardizzoni A., Boni L., Tiseo M., et al. CISCA (CISplatin versus CArboplatin) Meta-analysis Group Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst: 2007; 99 11 847 857
9. Schiller J. H., Harrington D., Belani C. P., et al. Eastern Cooperative Oncology Group Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med: 2002; 346 2 92 98 (Pubitemid 34438899)
10. Herbst R. S., Khuri F. R., Lu C., et al. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy. Cancer: 2002; 95 2 340 353 (Pubitemid 34787601)
11. Jiang J., Liang X., Zhou X., Huang R., Chu Z., Zhan Q. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy- naïve advanced non-small-cell lung cancer in the era of third-generation agents. J Cancer Res Clin Oncol: 2013; 139 1 25 38
12. Molina J. R., Adjei A. A. The role of Pemetrexed (Alimta, LY231514) in lung cancer therapy. Clin Lung Cancer: 2003; 5 1 21 27 (Pubitemid 36974736)
13. Scagliotti G. V., Parikh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol: 2008; 26 21 3543 3551
14. Socinski M. A., Schell M. J., Peterman A., et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol: 2002; 20 5 1335 1343 (Pubitemid 34182817)
15. Soon Y. Y., Stockler M. R., Askie L. M., Boyer M. J. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol: 2009; 27 20 3277 3283
16. Sandler A., Gray R., Perry M. C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med: 2006; 355 24 2542 2550 (Pubitemid 44917502)
17. Socinski M. A., Langer C. J., Huang J. E., et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol: 2009; 27 31 5255 5261
18. Pirker R., Pereira J. R., Szczesna A., et al. FLEX Study Team Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet: 2009; 373 9674 1525 1531
19. Lynch T. J., Patel T., Dreisbach L., et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol: 2010; 28 6 911 917
20. Paz-Ares L., De Marinis F., Dediu M., et al. PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLS). J Clin Oncol: 2012; 30 (suppl): Abstract LBA7507
21. Ciuleanu T., Brodowicz T., Zielinski C., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet: 2009; 374 9699 1432 1440
22. Fidias P. M., Dakhil S. R., Lyss A. P., et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol: 2009; 27 4 591 598
23. Sridhar S. S., Seymour L., Shepherd F. A. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol: 2003; 4 7 397 406 (Pubitemid 36833681)
24. Cappuzzo F., Ciuleanu T., Stelmakh L., et al. SATURN investigators Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol: 2010; 11 6 521 529
25. Shepherd F. A., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol: 2000; 18 10 2095 2103 (Pubitemid 30324363)
26. Hanna N., Shepherd F. A., Fossella F. V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol: 2004; 22 9 1589 1597 (Pubitemid 41079796)
27. Shepherd F. A., Rodrigues Pereira J., Ciuleanu T., et al. National Cancer Institute of Canada Clinical Trials Group Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med: 2005; 353 2 123 132 (Pubitemid 41058344)
28. Noble J., Ellis P. M., Mackay J. A., Evans W. K. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol: 2006; 1 9 1042 1058 (Pubitemid 47181377)
29. Crinò L., Mosconi A. M., Scagliotti G., et al. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol: 1999; 17 7 2081 2085 (Pubitemid 29318838)
30. Lara P. N. Jr, Gumerlock P. H., Mack P. C., et al. Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial. Clin Lung Cancer: 2004; 6 2 102 107 (Pubitemid 39440207)
31. Santoro A., Maiorino L., Santoro M. Second-line with vinorelbine in the weekly monochemotherapy for the treatment of advanced non-small cell lung cancer. Lung Cancer: 1994; 11 S130
32. Di Maio M., Chiodini P., Georgoulias V., et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol: 2009; 27 11 1836 1843
33. Fossella F. V., DeVore R., Kerr R. N., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol: 2000; 18 12 2354 2362 (Pubitemid 30415821)
34. Miller V. A., Fossella F. V., DeVore R., et al. Docetaxel benefits lung cancer symptoms and quality of life in a randomized phase III study of non-small cell lung cancer patients previously treated with platinum-based therapy. Proc Am Soc Clin Oncol: 1999; 18 491a
35. Dancey J., Shepherd F., Ramlau R., et al. Quality of life assessment in a randomized study of taxotere versus best supportive care in non-small cell lung cancer patients previously treated with platinum-based chemotherapy. Proc Am Soc Clin Oncol: 1999; 18 491a
36. Giaccone G., Herbst R. S., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol: 2004; 22 5 777 784 (Pubitemid 41103588)
37. Herbst R. S., Giaccone G., Schiller J. H., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol: 2004; 22 5 785 794 (Pubitemid 41103589)
38. Gatzemeier U., Pluzanska A., Szczesna A., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol: 2007; 25 12 1545 1552 (Pubitemid 46733081)
39. Herbst R. S., Prager D., Hermann R., et al. TRIBUTE Investigator Group TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol: 2005; 23 25 5892 5899
40. Mok T. S., Wu Y. L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med: 2009; 361 10 947 957
41. Rosell R., Carcereny E., Gervais R., et al. Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol: 2012; 13 3 239 246
42. Zhou C., Wu Y. L., Chen G., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol: 2011; 12 8 735 742
43. Maemondo M., Inoue A., Kobayashi K., et al. North-East Japan Study Group Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med: 2010; 362 25 2380 2388
44. Mitsudomi T., Morita S., Yatabe Y., et al. West Japan Oncology Group Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol: 2010; 11 2 121 128
45. Yang J. C., Schuler M. H., Yamamoto N., et al. LUX-Lung3: a randomized, open label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol: 2012; 30 (suppl): Abstract LBA7500
46. Kim D. W., Ahn M. J., Shi Y., et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol: 2012; 30 (suppl): Abstract 7533
47. Camidge D. R., Bang Y. J., Kwak E. L., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol: 2012; 13 10 1011 1019
48. Tsao M. S., Aviel-Ronen S., Ding K., et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol: 2007; 25 33 5240 5247 (Pubitemid 350232256)
49. Pao W., Wang T. Y., Riely G. J., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med: 2005; 2 1 e17
50. Janne P. A., Shaw A. T., Pereira J. R., et al. Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). J Clin Oncol: 2012; 30 (suppl): Abstract 7503
51. Bergethon K., Shaw A. T., Ou S. H., et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol: 2012; 30 8 863 870
52. Shaw A. T., Camidge D. R., Engelman J. A., et al. Clinical activity of crizotinib in advanced non-small cell lung cancer (NSCLC) harboring ROS1 gene rearrangement. J Clin Oncol: 2012; 30 (suppl): Abstract 7508
53. Suehara Y., Arcila M. E., Dela Cruz Drillon A. E., et al. KIF5B-RET: Discovery of a novel fusion oncogene in lung adenocarcinomas by a systematic screen for tyrosine kinase fusions and identification of patients for a RET targeted therapy trial. J Clin Oncol: 2012; 30 (suppl): Abstract 7578
54. Paik P. K., Arcila M. E., Fara M., et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol: 2011; 29 15 2046 2051
55. Marchetti A., Felicioni L., Malatesta S., et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol: 2011; 29 26 3574 3579
56. Brahmer J. R., Horn L., Antonia S., et al. Clinical activity and safety of anti-PD1 (BMS-936558, MDX-1106) in patients with advanced non-small-cell lung cancer (NSCLC). J Clin Oncol: 2012; 30 (suppl): Abstract 7509
57. ®); Non-Small Cell Lung Cancer: Version 2. 2012. Available at: http://www.tri-kobe.org/nccn/ guideline/lung/english/non-small.pdf
58. Meyerson M., Gabriel S., Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet: 2010; 11 10 685 696
59. Paik P. K., Hasanovic A., Wang L., et al. Multiplex testing for driver mutations in squamous cell carcinomas of the lung. J Clin Oncol: 2012; 30 (suppl): Abstract 7505
60. Sequist L. V., Heist R. S., Shaw A. T., et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol: 2011; 22 12 2616 2624